These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G. Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951 [Abstract] [Full Text] [Related]
4. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Ruf BR, Colberg K, Frick M, Preusche A. Infection; 2004 Aug 27; 32(4):191-8. PubMed ID: 15293073 [Abstract] [Full Text] [Related]
7. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B. Vaccine; 2007 Dec 21; 26(1):119-27. PubMed ID: 18063446 [Abstract] [Full Text] [Related]
10. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. Zuccotti G, Amendola A, Viganò A, Pariani E, Zappa A, Pogliani L, Giacomet V, Savarino A, Podestà A, Rottoli A, Tanzi E, Zanetti A, Radaelli G. Vaccine; 2007 Sep 17; 25(37-38):6692-8. PubMed ID: 17697730 [Abstract] [Full Text] [Related]
13. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. de Bruijn IA, Nauta J, Gerez L, Palache AM. Virus Res; 2004 Jul 17; 103(1-2):139-45. PubMed ID: 15163502 [Abstract] [Full Text] [Related]
14. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A. J Infect Dis; 2009 Sep 15; 200(6):841-8. PubMed ID: 19673651 [Abstract] [Full Text] [Related]
17. Efficacy of intranasal virosomal influenza vaccine in the prevention of recurrent acute otitis media in children. Marchisio P, Cavagna R, Maspes B, Gironi S, Esposito S, Lambertini L, Massimini A, Herzog C, Principi N. Clin Infect Dis; 2002 Jul 15; 35(2):168-74. PubMed ID: 12087523 [Abstract] [Full Text] [Related]
18. The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: data from a randomized, Phase III study. Esposito S, Marchisio P, Montinaro V, Bianchini S, Weverling GJ, Pariani E, Amendola A, Fabiano V, Pivetti V, Zanetti A, Zuccotti GV. Vaccine; 2012 Nov 19; 30(49):7005-12. PubMed ID: 23059357 [Abstract] [Full Text] [Related]
19. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Radosević K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, Zambon M, Weverling GJ, Uytdehaag F, Goudsmit J. Vaccine; 2008 Jul 04; 26(29-30):3640-6. PubMed ID: 18514980 [Abstract] [Full Text] [Related]